Advertisement

Evaluation and Management of Hypertrophic Cardiomyopathic Patients Through Noncardiac Surgery and Pregnancy

  • Nadia B. Hensley
  • Theodore P. Abraham
Chapter

Abstract

Due to the prevalence of hypertrophy cardiomyopathy (HCM) (1:500), anesthesiologists, cardiologists, surgeons and obstetricians will encounter these patients and need to thoroughly understand their disease in order to understand the risk that noncardiac surgery and pregnancy imposes upon them. Patients with HCM have genotypic and phenotypic variability. Indeed a subgroup of these patients exhibits the HCM genotype but not the phenotype (left ventricular hypertrophy). There are a number of treatment modalities for these patients including pharmacotherapy to control symptoms, implantable cardiac defibrillators to manage malignant arrhythmias, and surgical myectomy and alcohol septal ablation to decrease the left ventricular hypertrophy and outflow obstruction. In this chapter, we will discuss how management of these patients perioperatively is vital to improving their survivability and morbidity when they undergo noncardiac surgery, either electively or emergently. We will also discuss the peripartum management of the HCM patient since the physiologic changes of pregnancy can have either a salubrious or detrimental effect on the pathophysiology of HCM.

Keywords

Hypertrophic cardiomyopathy Preoperative evaluation Peripartum evaluation Noncardiac surgery Emergent surgery Left ventricular outflow tract obstruction 

Notes

Acknowledgements

We thank Ms. Samantha Livingston and the staff of the Johns Hopkins Center of Excellence, and Drs. MaryBeth Brady and Daniel Nyhan and Ms. Mary Ann Anderson for their support in the preparation of this manuscript.

Conflict of Interest

None of the authors have any conflicts.

References

  1. 1.
    Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Hreybe H, et al. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006;29(2):65–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Haering JM, et al. Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. Anesthesiology. 1996;85(2):254–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Fleisher LA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50(17):1707–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Maron BJ, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687–713.PubMedCrossRefGoogle Scholar
  6. 6.
    Olivotto I, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Maron MS, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Maron BJ, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281(7):650–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Spirito P, et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336(11):775–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Maron MS, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Maron MS, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303.PubMedCrossRefGoogle Scholar
  13. 13.
    Olivotto I, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Maron BJ, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10(4):733–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Fleisher LA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2009;120(21):e169–276.PubMedCrossRefGoogle Scholar
  16. 16.
    Afonso L, et al. Two-dimensional strain profiles in patients with physiological and pathological hypertrophy and preserved left ventricular systolic function: a comparative analyses. BMJ Open. 2012;2(4).Google Scholar
  17. 17.
    Autore C, et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45(7):1076–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Angelotti T, et al. Anesthesia for older patients with hypertrophic cardiomyopathy: is there cause for concern? J Clin Anesth. 2005;17(6):478–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Wysokinski WE, McBane 2nd RD. Periprocedural bridging management of anticoagulation. Circulation. 2012;126(4):486–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Douketis JD, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):299S–339.PubMedCrossRefGoogle Scholar
  22. 22.
    Blackshear JL, et al. Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc. 2011;86(3):219–24.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Udelson JE, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Sherrid MV, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Turner GM, Oakley CM, Dixon HG. Management of pregnancy complicated by hypertrophic obstructive cardiomyopathy. Br Med J. 1968;4(5626):281–4.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Oakley GD, et al. Management of pregnancy in patients with hypertrophic cardiomyopathy. Br Med J. 1979;1(6180):1749–50.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Stergiopoulos K, Shiang E, Bench T. Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol. 2011;58(4):337–50.PubMedCrossRefGoogle Scholar
  28. 28.
    Sebastien K, van der Smagt JJ, van den Berg MP. Systematic review of pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail. 2011;13:584–94.CrossRefGoogle Scholar
  29. 29.
    Avila WS, et al. Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy. Arq Bras Cardiol. 2007;88(4):480–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Frishman WH, Chesner M. Beta-adrenergic blockers in pregnancy. Am Heart J. 1988;115(1 Pt 1):147–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Rowan JA, et al. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol. 2003;43(2):123–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Pryn A, et al. Cardiomyopathy in pregnancy and caesarean section: four case reports. Int J Obstet Anesth. 2007;16(1):68–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Division of Cardiac Anesthesia, Department of Anesthesiology and Critical Care MedicineJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Division of CardiologyJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of CardiologyJohns Hopkins HospitalBaltimoreUSA

Personalised recommendations